ABSTRACT: Hematopoietic cell transplantation (HCT) from HLA-identical sibling donors has curative potential for ␤-thalassemia. The probability of surviving free of thalassemia under these conditions is approximately 85%. The application of this therapy is limited because many patients lack an HLA-identical sibling donor. HLA-mismatched stem cell transplantation for thalassemia is severely restricted by graft rejection and the risks for graftversus-host disease (GVHD). Thus, the development of a novel method that facilitates immunological tolerance and improves the safety of HLA-mismatched HCT would greatly expand the opportunity of HCT for thalassemia patients. We hypothesized that removal of T cells from the donor hematopoietic stem cell preparation and subsequent add-back after photochemical treatment with S-59, a psoralen, would promote and stabilize the engraftment and significantly reduce the risk of GVHD. This was tested in a MHC-mismatched HCT model of murine thalassemia. S-59-treated T cells were infused simultaneously with bone marrow-derived stem cells into mice with a heterozygous deletion of one ␤-globin alleles that had been conditioned with a sublethal dose of total body irradiation. Mice that received treated T cells showed increased engraftment compared to those that did not receive T cells. T-cell treatment improved survival without GVHD compared to recipients that received untreated T cells. We conclude that photochemical treatment of T cells facilitates engraftment and minimizes GVHD in allo-HCT for murine thalassemia, and sets the stage for further development of such protocols for the treatment of patients with thalassemia.
INTRODUCTION
Allogeneic, hematopoietic cell transplant (allo-HCT) has curative potential for hemoglobinopathies, even when there is mixed chimerism (MC) after HCT. However, limitations of current transplantation therapy, including lack of appropriate donors, the toxicity of myeloablative conditioning regimens, graft rejection, and graftversus-host disease (GVHD) limit this therapy. Worldwide, only approximately 2500 patients with thalassemia major and approximately 250 with sickle cell disease have been treated by allo-HCT. This relatively low number results principally from the limited availability of HLA-identical sibling donors. Graft rejection, life-threatening GVHD, and infections due to immunosuppressive regimens designed to prevent GVHD limit the application in mismatched settings. These problems are in large part due to the dualistic role that T cells play in HCT. On the one hand, donor T cells play an important role in successful stem cell engraftment, partially by releasing cytokines that promote stem cell proliferation and by overcoming residual host immunological responses against donor cells. 1 This positive function of T cells is counteracted by GVHD promoted by the proliferation of donor T cells. 2 The goal of this study was to test a novel strategy that would allow the donor T cells to facilitate engraftment of stem cells without causing GVHD by impairment of their ability to proliferate. Psoralens, including S-59, reversibly intercalate into DNA and RNA. Upon exposure to ultraviolet light, S-59 reacts with pyrimadine bases to form covalent monoadducts that crosslink DNA and renders the cells incapable of proliferation. By use of appropriate low-dose S-59, treatment protocols that incapacitated proliferation were shown to maintain the immunologically viability of T cells, their ability to synthesize and release cytokines, as well as other trophic factors, and to maintain their cytolytic activity. We hypothesized that this approach offers the opportunity to remove T cells from the donor stem cell preparation, treat them with S-59, and add them back prior to infusion into the recipient, with the expectation that engraftment will be facilitated without the risk for GVHD. We conducted MHCmatched and MHC-mismatched HCT in a murine model of thalassemia to test this hypothesis.
METHODS

Mice
Mice heterozygous for a complete deletion of the β-globin gene (C57BL6/J ∆β/ + 3 ) were obtained from Jackson Laboratories (Bar Harbor, ME) and propagated in our animal facility. The imbalance of globin production results in a β-thalassemic phenotype (TABLE 1) . The animals show a lower hematocrit and hemoglobin, increased reticulocyte counts, and increased spleen size, characteristic for increased erythropoiesis. Red blood cell (RBC) indices show typical thalassemic features, and the animals experience ineffective erythropoiesis and shortened red cell survival similar to human thalassemia intermedia. These mice were used as recipients for stem cells derived from donor mice (C57BL6/J +/+, AKR, or C57BL/6-TgN(ACTbEGFP)1Osb mice expressing Green Fluorescent Protein (GFP) also obtained from Jackson Labs and propagated in our animal facility.
Transplantation and T-Cell Add-Back
Donor Cells
Adult mice, two to three months old were sacrificed by CO 2 intoxication. Spleens, femurs, tibia, and fibulae were removed under aseptic conditions and placed in DMEM. Bone marrow was obtained by flushing the leg bones with DMEM using a syringe; the cell suspension was then strained, washed, and resuspended. Spleen cell suspensions were strained, washed, and RBCs were removed by lysis with hemolytic Gey's solution. Magnetic anti-CD4 and CD8 microbeads (Miltenyi Biotec, Auburn, CA) were added to bone marrow and spleen-derived cell suspensions, and CD4+ and CD8+ T cells were removed on magnetic cell separation columns according to the manufacturer's instructions. The T-cell fraction was tested for purity by flowcytometry. CD4+ and CD8+ cells separated from the bone marrow were discarded (T-cell depletion); CD4+ and CD8+ cells from the spleen were preserved for T-cell add-back. Psoralen-treated T cells were prepared by incubating 2 × 10 6 cells in PBS with 5% FBS and 2 nM S-59 for 5 min, followed by 4.5-min exposure to UV light. The cells were then washed 3 times to remove unincorporated S-59 and resuspended in DMEM.
Transplant
Thalassemic mice were given 600-750 cGy gamma irradiation 24 h prior to transplant. Mice received 200 µL tail-vein infusion of 1 × 10 7 , or none (irradiated controls) matched (C57BL6/J +/+, C57BL/6-TgN(ACTbEGFP)1Osb) or unmatched (AKR) cells from bone marrow, to which none, 3 * 10 6 S-59-treated, or untreated T cells were added. 
Follow-Up
White blood cell chimerism in transplant recipients was assessed by a quantitative polymerase chain reaction using a marker sequence on the Y chromosome (for male/female donor recipient pairs) or flowcytometric measurement of the MHC class I antigens H2-k k (AKR) and H2-k b (C57BL6) (for unmatched transplants). RBC parameters of the thalassemic mice are significantly different from the donor mice and allowed the assessment of RBC chimerism in the peripheral blood. Bone marrow-derived stem cells from C57BL/6-TgN(ACTbEGFP)1Osb mice expressing Green Fluorescent Protein (GFP) were used to follow the fate of stem cells in recipients and allowed evaluation of stem cell homing to organs other than the blood cell, generating compartments by fluorescent microscopy. Changes in hematologic and RBC parameters were measured by measurement of RBC indices using a Technicon H3 analyzer, and RBC turnover was assessed by monitoring the survival of biotinylated RBCs. 4 
RESULTS
Non-transplanted β-thalassemic controls survived up to 7.5 Gy irradiation and were indistinguishable from their non-irradiated littermates on sacrifice at 11 months, setting the limits for nonlethal radiation. In MHC-matched transplants, white blood cell chimerism was 50 ± 11%, after administration of non-myeloablative total body irradiation (7.5 Gy) in animals at 9 weeks posttransplant. Chimerism increased over time and, at 11 months after HCT, the hematocrit increased from approximately 33% in thalassemic animals or irradiated controls to 43% in the transplanted group. The reticulocyte population was reduced from approximately 14% in control animals to 3.7% after HCT. RBC mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular volume, and cell deformability and RBC turnover were indistinguishable from that of normal mice at sacrifice (TABLE 2) . Both irradiated and non-irradiated β-thalassemic animals had enlarged spleens and a high number of splenic RBC precursors. In contrast, after HCT animals showed dramatic reductions in spleen size and splenic RBC precursor number to values similar to that of normal mice (TABLE 3) . In unrelated, MHC- mismatched transplantation (AKR into C57BL6), thalassemic recipient mice were given 7.5 Gy gamma irradiation 24 h before the infusion of 1 × 10 7 AKR T-celldepleted bone marrow cells to which either untreated, photochemically treated, or no AKR-derived T cells were added. Add-back of untreated AKR-derived T cells resulted in death from GVHD within 10 days. In contrast, recipients who received S-59-treated T cells had resolution of anemia similar to after MHC-matched transplantation as indicated above, without evidence of acute or chronic GVHD. Addition of S-59-treated T cells significantly improved the likelihood of engraftment. Whereas 20% of the C57BL6 thalassemic mice that received AKR donor cells had donor engraftment (sufficient for resolution of the anemia), the success rate increased to 80% when S-59-treated T cells were added back to the stem cell inoculum. When S-59-treated donor T cells were labeled with biotin, no biotinylated T cells could be identified in the peripheral blood by flow cytometry 10 days after transplantation, indicating these T cells are short-lived and do not proliferate. RBC survival improved over time and was normal at 52 weeks (FIG. 1) . Upon sacrifice, most of the T cells in the peripheral blood of the recipients that lacked anemia were of donor origin, as determined by flow cytometry.
To investigate the fate of stem cells in other organs, donor stem cell preparations from GFP-expressing C57BL6 mice were infused in thalassemic animals. As expected, based upon the results above, the thalassemic recipient animals experienced resolution of the thalassemic phenotype over time. In addition to a normalization of the RBC population, these animals had GFP containing platelets and white blood cells in the peripheral blood. In the spleen of these mice, significant numbers of GFPexpressing cells were observed. FIGURE 2A shows the distribution of GFP-expressing cells in the spleen. In addition, GFP-expressing cells were found in other organs. FIGURE 2B and 2D show sections of the liver positive for GFP, indicating cells of donor origin. When labeled with antibody against von Willebrand factor, co-labeled cells were observed in the liver (FIG. 2C and 2E ), indicating that hepatic endothelial cells of these transplanted thalassemic animals were derived from donor cells. 
DISCUSSION
Our data indicate that photochemically treated S-59 T-cell add-backs can enhance engraftment of bone marrow-derived stem cells across an MHC barrier without causing GVHD in a thalassemic mouse model. Success of engraftment was assessed by comparison of RBC characteristics and reticulocyte percentage in the peripheral blood between thalassemic mice, wild-type mice, and transplanted thalassemic mice. RBC analysis of peripheral blood, rather than the measurement of white cell chimerism, is appropriate in the setting of hemoglobinopathies because the primary defect involves hemoglobin, and disease severity is often directly related to RBC characteristics. Selective pressure within the chimeric RBC compartment due to host hemoglobin disorders may favor donor cell expansion over expansion of host cells. Ineffective erythropoiesis, or apoptosis of RBC precursors, is a characteristic of thalassemia. Donor-derived RBC precursors will have a higher chance of survival in spleen or marrow, and donor-derived reticulocytes have an improved ability to enter the peripheral blood. Moreover, because RBC derived from donor stem cells have an increased survival in the peripheral blood, chimerism based on analysis of precursors may underestimate the result of the transplant. Therefore, direct measurement of peripheral blood RBC characteristics is likely as important as white cell or marrow studies for patients transplanted for thalassemia or sickle cell disease. In our study, both RBC indices and white blood cell chimerism analyses suggested an all-or-none replacement of host cells in successful transplants one year after the procedure. Adjustments in the conditioning and/or treatment regimens may allow for creation of mixed RBC chimeras that retain some abnormal (thalassemic) hemoglobin production but are effectively cured of clinical disease complications.
Graft failure and GVHD are major challenges in allogeneic stem cell transplantation for any indication. Our data suggest that S-59-treated donor T cells can enhance engraftment across a MHC-histocompatibility barrier without causing severe GVHD. This strategy is appealing for clinical application in hemoglobinopathies, autoimmune disorders, and other non-malignant indications since these disorders may be more amenable to minimally myeloablative conditioning regimens than malignant disorders because these do not rely on a T-cell graft-versus-leukemia effect. The mechanism of enhanced stem cell engraftment is unclear, but is likely related to the preservation of the allo-reactivity of mature donor T cells. Prior studies have demonstrated that S-59-treated T cells retain their ability to synthesize and secrete IL-2, express the IL-2 receptor (CD25) and CD69, an early activation marker, upon ex vivo stimulation with anti-CD3 monoclonal antibody. T-cell depletion of the donor stem cell preparation results in an increased risk of graft failure, [5] [6] [7] which is confirmed in our study. Only 20% of the mice showed stable engraftment in the absence of T cells. In contrast, when S-59-treated T cells were added to the donor stem cell preparation, 80% of the thalassemic mice showed successful engraftment, suggesting that S-59 treatment preserved the allo-reactive nature of mature donor T cells.
In the MHC-mismatched transplantation setting, S-59 treatment of donor T cells proved to be required for donor engraftment. Addition of MHC-mismatched T cells not treated by S-59 caused severe GVHD. Prior studies have demonstrated that S-59 treatment inhibits T-cell proliferation, which is central to GVHD pathophysiology. 8 GVHD, which in our studies was simply defined by premature death within 10 days after HCT, occurred in all cases when untreated AKR-derived T cells were given to C57BL6 mice. In contrast, this was not observed in recipients that received the same number of S-59-treated T cells. These data support the hypothesis that the elimination of donor T-cell proliferation and expansion minimizes GVHD.
Further characterization of the T-cell repertoire in these mice is necessary to determine the origin and immunological activity of these cells posttransplant. No biotinylated T cells that were added at the time of transplant could be found two weeks following transplant, suggesting that all adult donor T cells added at the time of transplant were removed from the peripheral blood. Our data further indicate that one year after treatment virtually all T cells in the peripheral blood are of donor origin. This suggests that the T-cell repertoire represented the progeny of stably engrafted stem cell-generated donor T cells that had undergone thymic education in the host, with central deletion of alloreactive donor T cells. Future studies using labeled T cells, lymphoproliferative assays directed against third-party antigens, TREC analysis, spectratyping for T-cell repertoire, and flow cytometry for markers of T-cell activation will clarify the effect on the T-cell repertoire after MHC-mismatched transplantation with S-59-treated T-cell add-backs.
It has been suggested that tissue regeneration and repair may occur after bone marrow and cord blood-transplantation. Under these conditions, we show that resolution of the anemia seemed indeed to be accompanied by stem cell homing to other tissues, as demonstrated by marking of donor hematopoietic cells with GFP. In addition to the expected presence of GFP-expressing cells in marrow and spleen, we find evidence of GFP-expressing cells in other tissues. We used unfractionated bone marrow from GFP "marked" donor mice, which does not allow the definition of the type of cells that home to other tissues. While this approach did not lend itself to an identification of the cell-type of origin that was observed in non-hematopoietic organs, in clinical practice donor stem cell preparations are similarly heterogenous in nature. Our data do not enable us to conclude whether these cells homed directly from the donor stem cell infusate shortly after transplantation or if the donor cells migrated from spleen or marrow hematopoietic environments to tissues at some later time after transplantation. Whereas double labeling and analysis by fluorescent microscopy shows that cells positive for endothelial markers also express GFP, additional studies are required to support any conclusions about the potential for benefit with repair of tissues other than the blood cell-generating compartments after HCT. This would require some demonstration that the contribution by donor-derived cells in organs damaged by the underlying hemoglobinopathy is sufficient to effect a clinically significant improvement in recipient organ function in the long-term. Together these results demonstrate the potential to produce a cure for murine thalassemia using a limited myeloablative protocol with mismatched donors and photochemically treated T-cell add-backs. These studies suggest a future treatment strategy for patients with human hemoglobinopathy that reduces the toxicity of conventional BMT and may expand to non-HLA-matched donors to produce a clinical cure.
